Mechanisms of Jisheng-Wumei tablet in laryngeal cancer treatment: a network pharmacology analysis of baicalein’s targeting of cytochrome C for laryngeal cancer inhibition

Baicalein is identified as the key active ingredient in JSWMT, targeting CYCS to inhibit the growth of laryngeal cancer cells. This investigation highlights baicalein's potential mechanism of action and underscores the importance of integrating traditional Chinese medicine with contemporary cancer treatment strategies, offering a novel approach to laryngeal cancer therapy.